Kala Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   5 Diseases   2 Products   0 Trials   121 News 


12»
  • ||||||||||  Eysuvis (loteprednol etabonate nano-suspension 0.25%) / Kala Pharma
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection (clinicaltrials.gov) -  Jan 9, 2023   
    P4,  N=71, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=116 --> 71 | Trial completion date: Feb 2023 --> Aug 2023 | Trial primary completion date: Jan 2023 --> Jul 2023
  • ||||||||||  Inveltys (loteprednol etabonate nano-suspension 1%) / Kala Pharma, Eysuvis (loteprednol etabonate nano-suspension 0.25%) / Kala Pharma
    Both Eysuvis and Inveltys (Twitter) -  May 25, 2022   
  • ||||||||||  Clinical, Review, Journal:  A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. (Pubmed Central) -  Apr 9, 2022   
    Nanoparticles and ocular iontophoresis form the next wave of DDS that have the potential to replace topical steroids eye-drops as the treatment of choice for anterior segment inflammation. With the current relentless pace of ophthalmic drug delivery research, the pursuit of a new standard of treatment that eliminates the problems of low bioavailability and patient compliance may soon be realised.
  • ||||||||||  Tyrvaya (varenicline nasal spray) / Oyster Point Pharma
    Journal:  Varenicline nasal spray (Tyrvaya) for dry eye disease. (Pubmed Central) -  Feb 8, 2022   
    Eysuvis is the first FDA-approved ocular corticosteroid indicated for dry eye disease. No abstract available
  • ||||||||||  Inveltys (loteprednol etabonate nano-suspension 1%) / Kala Pharma
    Journal:  KPI-121 1% for pain and inflammation in ocular surgery. (Pubmed Central) -  Dec 2, 2021   
    Results from clinical trials demonstrate that KPI-121 1% is effective and well tolerated. KPI-121 1% uses mucopenetrative technology for ophthalmic use and is the only US FDA-approved twice-daily ocular corticosteroid indicated for the treatment of inflammation and pain after ocular surgery.
  • ||||||||||  Eysuvis (loteprednol etabonate nano-suspension 0.25%) / Kala Pharma
    EYSUVIS (Twitter) -  Nov 15, 2021   
  • ||||||||||  loteprednol etabonate / Generic mfg.
    Safety and Efficacy of KPI-121 Ophthalmic Suspension 0.25% for Dry Eye Disease in Three Phase Three Randomized Controlled Trials () -  Jul 19, 2021 - Abstract #ASCRSASOA2021ASCRS_ASOA_275;    
    Significant improvements in CH at Day 15 were demonstrated in all 3 trials, STRIDE 1 (p<0.0001), STRIDE2 (p<0.0001), and STRIDE 3 (p<0.0001).The most frequently reported adverse event in all 3 trials was instillation site pain (4.9% for KPI-121 0.25% and 4.0% for vehicle).The incidence of intraocular pressure increase was comparable to vehicle.ConclusionIn all three Phase 3 trials, KPI-121 0.25% improved both signs and symptoms of DED when dosed QID for 2 weeks. KPI 121 0.25% appeared to be safe and well-tolerated and the incidence of IOP elevation was similar between the KPI-121 0.25% and vehicle arms.
  • ||||||||||  Eysuvis (loteprednol etabonate nano-suspension 0.25%) / Kala Pharma
    Journal:  Loteprednol 0.25% (Eysuvis) for dry eye disease. (Pubmed Central) -  May 26, 2021   
    KPI 121 0.25% appeared to be safe and well-tolerated and the incidence of IOP elevation was similar between the KPI-121 0.25% and vehicle arms. No abstract available